Suppr超能文献

Tropheryma whipplei在MRC5细胞中的抗生素敏感性

Antibiotic susceptibility of Tropheryma whipplei in MRC5 cells.

作者信息

Boulos Areen, Rolain Jean-Marc, Raoult Didier

机构信息

Unité des Rickettsies, CNRS UMR 6020, IFR48, Faculté de Médecine, Université de la Méditerranée, 13385 Marseille Cedex 05, France.

出版信息

Antimicrob Agents Chemother. 2004 Mar;48(3):747-52. doi: 10.1128/AAC.48.3.747-752.2004.

Abstract

Whipple's disease is considered a rare chronic disease with a broad spectrum of clinical manifestations. Several antibiotics have been used for the treatment of this disease, and the current reference treatment was determined empirically on the basis of only a few clinical observations. Patients should be treated for months, and many relapse after antibiotic withdrawal. We report here the first extensive study on the susceptibilities of three reference strains of Tropheryma whipplei to antibiotic in cell culture by using a real-time PCR assay as previously described. We found that doxycycline, macrolides, ketolides, aminoglygosides, penicillin, rifampin, teicoplanin, chloramphenicol, and trimethoprim-sulfamethoxazole were active, with MICs ranging from 0.25 to 2 microg/ml. Vancomycin was somewhat active at an MIC of 10 microg/ml. We found heterogeneity in the susceptibility to imipenem, with one strain being susceptible and the two other strains being resistant. Cephalosporins, colimycine, aztreonam, and fluoroquinolones were not active. We also demonstrated that a combination of doxycycline and hydroxychloroquine was bactericidal. This combination has been shown to be active in the treatment of patients suffering from chronic infections with Coxiella burnetii, a bacterium that is also found intracellularly in acidic vacuoles. We believe, then, that this combination therapy should be further evaluated in clinical trials for the treatment of Whipple's disease.

摘要

惠普尔病被认为是一种临床表现多样的罕见慢性病。已有多种抗生素用于治疗该疾病,目前的参考治疗方案仅基于少数临床观察经验性确定。患者需接受数月治疗,且许多人在停用抗生素后会复发。我们在此报告首次通过实时聚合酶链反应分析,对三株鞭毛虫样杆菌参考菌株在细胞培养中对抗生素的敏感性进行的广泛研究。我们发现强力霉素、大环内酯类、酮内酯类、氨基糖苷类、青霉素、利福平、替考拉宁、氯霉素和甲氧苄啶 - 磺胺甲恶唑具有活性,最低抑菌浓度(MIC)范围为0.25至2微克/毫升。万古霉素在MIC为10微克/毫升时具有一定活性。我们发现对亚胺培南的敏感性存在异质性,一株敏感,另外两株耐药。头孢菌素、黏菌素、氨曲南和氟喹诺酮类无活性。我们还证明强力霉素和羟氯喹啉联合使用具有杀菌作用。这种联合用药已被证明对患有慢性伯纳特立克次体感染的患者有效,伯纳特立克次体也是一种在酸性液泡内细胞内发现的细菌。因此,我们认为这种联合疗法应在惠普尔病治疗的临床试验中进一步评估。

相似文献

1
Antibiotic susceptibility of Tropheryma whipplei in MRC5 cells.
Antimicrob Agents Chemother. 2004 Mar;48(3):747-52. doi: 10.1128/AAC.48.3.747-752.2004.
2
Molecular evaluation of antibiotic susceptibility of Tropheryma whipplei in axenic medium.
J Antimicrob Chemother. 2005 Feb;55(2):178-81. doi: 10.1093/jac/dkh524. Epub 2005 Jan 13.
3
Treatment of classic Whipple's disease: from in vitro results to clinical outcome.
J Antimicrob Chemother. 2014 Jan;69(1):219-27. doi: 10.1093/jac/dkt310. Epub 2013 Aug 14.
4
In vitro activity of pentamidine against Tropheryma whipplei.
Int J Antimicrob Agents. 2011 Dec;38(6):545-7. doi: 10.1016/j.ijantimicag.2011.07.015. Epub 2011 Oct 17.
6
Failure and relapse after treatment with trimethoprim/sulfamethoxazole in classic Whipple's disease.
J Antimicrob Chemother. 2010 Sep;65(9):2005-12. doi: 10.1093/jac/dkq263. Epub 2010 Jul 17.
7
Whipple's disease and Tropheryma whipplei infections: when to suspect them and how to diagnose and treat them.
Curr Opin Infect Dis. 2018 Dec;31(6):463-470. doi: 10.1097/QCO.0000000000000489.
8
[Whipple's disease and Tropheryma whipplei infections in internal medicine. When to think about it? How to treat?].
Rev Med Interne. 2014 Dec;35(12):801-7. doi: 10.1016/j.revmed.2014.04.016. Epub 2014 Jun 2.
10
Tropheryma whipplei and Whipple's disease.
J Infect. 2014 Aug;69(2):103-12. doi: 10.1016/j.jinf.2014.05.008. Epub 2014 May 28.

引用本文的文献

1
Exploring protein inhibitors of through pharmacoinformatic approaches incorporating solubility-enhancing formulation insights.
Front Pharmacol. 2025 Aug 14;16:1630038. doi: 10.3389/fphar.2025.1630038. eCollection 2025.
4
Potential treatments of COVID-19: Drug repurposing and therapeutic interventions.
J Pharmacol Sci. 2023 May;152(1):1-21. doi: 10.1016/j.jphs.2023.02.004. Epub 2023 Feb 15.
5
Treatable Ataxias: How to Find the Needle in the Haystack?
J Mov Disord. 2022 Sep;15(3):206-226. doi: 10.14802/jmd.22069. Epub 2022 Sep 7.
6
Hydroxychloroquine in COVID-19 Patients: Pros and Cons.
Front Pharmacol. 2020 Nov 19;11:597985. doi: 10.3389/fphar.2020.597985. eCollection 2020.
8
Pathophysiology and Potential Therapeutic Candidates for COVID-19: A Poorly Understood Arena.
Front Pharmacol. 2020 Sep 17;11:585888. doi: 10.3389/fphar.2020.585888. eCollection 2020.
9
COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine.
Virol Sin. 2020 Dec;35(6):685-698. doi: 10.1007/s12250-020-00297-0. Epub 2020 Sep 30.
10
The C-C Chemokine Receptor Type 4 Is an Immunomodulatory Target of Hydroxychloroquine.
Front Pharmacol. 2020 Aug 28;11:1253. doi: 10.3389/fphar.2020.01253. eCollection 2020.

本文引用的文献

1
STAINING RICKETTSIAE IN YOLK-SAC CULTURES.
Stain Technol. 1964 May;39:135-40. doi: 10.3109/10520296409061219.
2
Culture of Tropheryma whipplei from human samples: a 3-year experience (1999 to 2002).
J Clin Microbiol. 2003 Aug;41(8):3816-22. doi: 10.1128/JCM.41.8.3816-3822.2003.
3
Tropheryma whipplei Twist: a human pathogenic Actinobacteria with a reduced genome.
Genome Res. 2003 Aug;13(8):1800-9. doi: 10.1101/gr.1474603.
4
Whipple's disease, genomics, and drug therapy.
Lancet. 2003 May 31;361(9372):1916. doi: 10.1016/S0140-6736(03)13533-7.
5
Molecular evaluation of antibiotic susceptibility: Tropheryma whipplei paradigm.
Antimicrob Agents Chemother. 2003 May;47(5):1658-64. doi: 10.1128/AAC.47.5.1658-1664.2003.
6
Sequencing and analysis of the genome of the Whipple's disease bacterium Tropheryma whipplei.
Lancet. 2003 Feb 22;361(9358):637-44. doi: 10.1016/S0140-6736(03)12597-4.
7
Molecular characterization of the vanE gene cluster in vancomycin-resistant Enterococcus faecalis N00-410 isolated in Canada.
Antimicrob Agents Chemother. 2002 Jun;46(6):1977-9. doi: 10.1128/AAC.46.6.1977-1979.2002.
8
Quantitative detection of Tropheryma whipplei DNA by real-time PCR.
J Clin Microbiol. 2002 Mar;40(3):1119-20. doi: 10.1128/JCM.40.3.1119-1120.2002.
9
Survival of Tropheryma whipplei, the agent of Whipple's disease, requires phagosome acidification.
Infect Immun. 2002 Mar;70(3):1501-6. doi: 10.1128/IAI.70.3.1501-1506.2002.
10
Use of aminoglycosides in treatment of infections due to intracellular bacteria.
Antimicrob Agents Chemother. 2001 Nov;45(11):2977-86. doi: 10.1128/AAC.45.11.2977-2986.2001.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验